Shares of CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.17 and traded as low as $0.14. CytoDyn shares last traded at $0.15, with a volume of 1,476,035 shares.
CytoDyn Trading Up 7.9 %
The firm has a 50-day moving average of $0.17 and a two-hundred day moving average of $0.18. The firm has a market capitalization of $148.93 million, a PE ratio of -3.00 and a beta of 0.25.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last released its quarterly earnings data on Monday, April 15th. The biotechnology company reported ($0.01) EPS for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
- Five stocks we like better than CytoDyn
- How to Effectively Use the MarketBeat Ratings Screener
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Investing In Preferred Stock vs. Common Stock
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
